Forxiga (dapagliflozin) has been approved in the
The approval by the
Forxiga (dapagliflozin)
Forxiga is approved for type-2 diabetes (T2D), HFrEF and chronic kidney disease (CKD) in more than 100 countries around the world including the US, the EU,
“This broader indication for Forxiga for the treatment of symptomatic chronic heart failure across the full ejection fraction range will help more patients to benefit from this well-tolerated and guideline-directed treatment,” commented
Heart failure
HF affects nearly 64 million people globally, according to a study published in the
The post Forxiga approved in EU for chronic heart failure appeared first on European Pharmaceutical Review.
© Russell Publishing Limited, 2023. All Rights Reserved., source